Trends in Parkinson's disease medication prescribing patterns in the UK: An interrupted time series analysis (2019-2024).
This study aimed to examine prescribing trends for Parkinson's disease (PD) medications in the United Kingdom from 2019 to 2024, focusing on the impact of guidelines from the American Academy of Neurology (AAN) and the National Institute for Health and Care Excellence (NICE) on the use of levod...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2025-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0324999 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849719143272546304 |
|---|---|
| author | Khalid Orayj |
| author_facet | Khalid Orayj |
| author_sort | Khalid Orayj |
| collection | DOAJ |
| description | This study aimed to examine prescribing trends for Parkinson's disease (PD) medications in the United Kingdom from 2019 to 2024, focusing on the impact of guidelines from the American Academy of Neurology (AAN) and the National Institute for Health and Care Excellence (NICE) on the use of levodopa and dopamine agonists (DAs). A repeated cross-sectional design was employed, using publicly available data to assess prescribing patterns across the four UK countries. An interrupted time series analysis with linear regression was performed to identify trends, comparing regions with England as the reference point. Levodopa remained the most prescribed PD medication across all UK regions, as revealed by the analysis. In England, levodopa prescriptions increased significantly after the introduction of AAN guidelines, while other regions displayed more stable trends. Northern Ireland exhibited a distinct pattern, with DAs prescribed more frequently than levodopa. The findings also indicated that Scotland and Wales were less responsive to AAN guidance. This study highlights the influence of clinical guidelines on PD prescribing practices in the UK, with regional variations suggesting possible demographic or healthcare system factors. Further research is required to understand these disparities and their implications for PD management. |
| format | Article |
| id | doaj-art-5d393fee55054fc3b63f16b64f8e97a3 |
| institution | DOAJ |
| issn | 1932-6203 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-5d393fee55054fc3b63f16b64f8e97a32025-08-20T03:12:12ZengPublic Library of Science (PLoS)PLoS ONE1932-62032025-01-01205e032499910.1371/journal.pone.0324999Trends in Parkinson's disease medication prescribing patterns in the UK: An interrupted time series analysis (2019-2024).Khalid OrayjThis study aimed to examine prescribing trends for Parkinson's disease (PD) medications in the United Kingdom from 2019 to 2024, focusing on the impact of guidelines from the American Academy of Neurology (AAN) and the National Institute for Health and Care Excellence (NICE) on the use of levodopa and dopamine agonists (DAs). A repeated cross-sectional design was employed, using publicly available data to assess prescribing patterns across the four UK countries. An interrupted time series analysis with linear regression was performed to identify trends, comparing regions with England as the reference point. Levodopa remained the most prescribed PD medication across all UK regions, as revealed by the analysis. In England, levodopa prescriptions increased significantly after the introduction of AAN guidelines, while other regions displayed more stable trends. Northern Ireland exhibited a distinct pattern, with DAs prescribed more frequently than levodopa. The findings also indicated that Scotland and Wales were less responsive to AAN guidance. This study highlights the influence of clinical guidelines on PD prescribing practices in the UK, with regional variations suggesting possible demographic or healthcare system factors. Further research is required to understand these disparities and their implications for PD management.https://doi.org/10.1371/journal.pone.0324999 |
| spellingShingle | Khalid Orayj Trends in Parkinson's disease medication prescribing patterns in the UK: An interrupted time series analysis (2019-2024). PLoS ONE |
| title | Trends in Parkinson's disease medication prescribing patterns in the UK: An interrupted time series analysis (2019-2024). |
| title_full | Trends in Parkinson's disease medication prescribing patterns in the UK: An interrupted time series analysis (2019-2024). |
| title_fullStr | Trends in Parkinson's disease medication prescribing patterns in the UK: An interrupted time series analysis (2019-2024). |
| title_full_unstemmed | Trends in Parkinson's disease medication prescribing patterns in the UK: An interrupted time series analysis (2019-2024). |
| title_short | Trends in Parkinson's disease medication prescribing patterns in the UK: An interrupted time series analysis (2019-2024). |
| title_sort | trends in parkinson s disease medication prescribing patterns in the uk an interrupted time series analysis 2019 2024 |
| url | https://doi.org/10.1371/journal.pone.0324999 |
| work_keys_str_mv | AT khalidorayj trendsinparkinsonsdiseasemedicationprescribingpatternsintheukaninterruptedtimeseriesanalysis20192024 |